Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
about
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farMLK3 Signaling in Cancer InvasionPhosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFRSecretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.Novel molecular imaging platform for monitoring oncological kinases.PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics.Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancerEGFR-mutated lung cancer: a paradigm of molecular oncology.Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma.Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo.Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts.The evolving role of the pathologist in the management of lung cancer.Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancerHBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Sex disparities in the association of lung adenocarcinoma with colorectal cancer.Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells.Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancerTrue local recurrences do not metastasize.The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.Genetic and epigenetic changes in lung carcinoma and their clinical implications.Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction.Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells.Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis.Druggable drivers of lung cancer.Advances in targeting the transforming growth factor β1 signaling pathway in lung cancer radiotherapy.Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion.Polymorphisms in genes related to epithelial-mesenchymal transition and risk of non-small cell lung cancer.Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.[Effects of Src on proliferation and invasion of lung cancer cells].
P2860
Q26745776-138152AD-5018-417D-B805-CEC4E8E9C6B1Q26746892-783D1D23-FFC6-4985-A6AF-DC32F1CB9B78Q27851872-875836DE-3EF5-4486-8397-AE61B3295749Q34000586-2249AD23-1773-4237-B199-0D9BEFEAA844Q34039242-7F4CDF09-DE07-461F-8823-9A16E298C4CFQ34213807-97B37D51-3F4B-4D8B-9CE6-F2A658F263E0Q34356166-2193D747-E808-4CDB-91CA-22CB89AA4338Q34406334-99664C89-D23E-4273-BFE0-554C4D6A5266Q35017125-17B2EF2A-6087-495E-A1FE-7CAEFDAB9EA3Q35119830-141978FA-03D1-4B72-BD09-3CD6DD25A3A1Q35227386-52A6928B-BA20-413D-9608-9BCA781E8704Q35563891-E3E5E80F-78DE-4117-9768-990A3FA5924EQ35951079-5839F43D-D163-495A-8E0B-DB55DCF8ED8DQ36022297-BD9C23C9-73A4-45A6-8A0C-4D1B685679E7Q36729450-D19C1182-257F-4E5D-BE79-E3612D847DF1Q37347517-8DFA0F37-1867-429F-8687-C318E79DF529Q37660692-38A6A6E6-A224-4CDB-9CBD-4EC81AD37AEDQ37701159-8DDB8220-0B3A-4CEE-B2A4-574A3093165CQ37832441-EE653F9E-124B-43DC-B088-2BFF3280D284Q37838120-1938734C-3926-46D9-AD2B-E977E69749A3Q37855515-431A12DE-0B8B-4F1D-990F-3B548F9734B9Q38701670-2ABF85BE-3E94-446B-BF9B-934D80095CD6Q39421577-09D4D2B5-63DF-4D2F-8AE5-81005C1A4EC6Q41594760-F03B2F3D-08AA-44F1-A786-F3FE683ECBE7Q41865343-CCA6AEFC-3F8A-4B6C-883A-01C3BBF6C01FQ42050622-5084F2B3-FEBB-4442-8589-89FEE5A48D4BQ42146311-55147B55-799A-42E1-A067-CB81A11C4E38Q42361474-9D8AC075-3A80-4B9A-8183-8F7FF5829BA4Q42568723-B5D37853-09E4-4C3E-8473-9C7A2248CF23Q42911901-15DD0372-7D49-47D2-8C80-49BE460B9421Q43251846-501FCA44-5A95-4D70-A653-992732DDBC1FQ47161252-48A78BC0-095A-4CAE-BB74-39263BC93D2BQ47254894-E2EDDB8A-3CBB-43F4-A6F0-F07120745BABQ50300068-E4972FB5-EF8E-44DA-B728-F92E5D55679BQ53287912-F68F7A2D-35B8-42C9-AC42-CD0BD75F3CDD
P2860
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Epidermal growth factor recept ...... role of individualized therapy
@ast
Epidermal growth factor recept ...... role of individualized therapy
@en
type
label
Epidermal growth factor recept ...... role of individualized therapy
@ast
Epidermal growth factor recept ...... role of individualized therapy
@en
prefLabel
Epidermal growth factor recept ...... role of individualized therapy
@ast
Epidermal growth factor recept ...... role of individualized therapy
@en
P2860
P1476
Epidermal growth factor recept ...... role of individualized therapy
@en
P2093
Adi F Gazdar
P2860
P2888
P356
10.1007/S10555-010-9201-Z
P577
2010-03-01T00:00:00Z